Temperature changes in vitrectomy

Article

Examining the temperature changes in the vitreous and retina and possible side effects

"Therapeutic hypothermia is being used more and more throughout medicine these days, with many benefits, but also with some possible bad side effects," he continued. "We determined that that we are in fact inducing hypothermia to the retina and vitreous during vitrectomy with unknown (but probably minimal) side effects."

Effect of temperature

"Fortunately," Dr Landers added, "using room temperature infusion fluid during a victrectomy, which induces hypothermia in the retina and vitreous (and probably other structures inside the eye, such as the lens) seems to have minimal side effects."

One of the main concerns and side effects of vitrectomy is cataract. "Many patients undergoing a vitrectomy develop a cataract in their lens sooner than in their nonvitrectomized eye. We don't know the reason for this. It is just possible that it is somehow related to the induced hypothermia... but this is still speculative," he explained.

The study

This prospective study, however, included only six patients and Dr Landers emphasized a need for further research to fully examine what possible effects this change in temperature could have. "Ideally, a larger and longerterm study shoud be performed, possibly even a controlled study that compares the effects of room temperature infusion fluid and warmer, possibly body temperature, infusion fluid to see if the warmed fluid produces fewer cataracts," Dr Landers said. "We are continuing our measurements to obtain larger data sets and we are also testing differing conditions, such as retinal detachments and other situations."

Special contributor

Dr Reece Landers, MD, is a vitreoretinal surgeon at the University of North Carolina, Chapel Hill, North Carolina, USA. He may be reached by Email: maurice_landers@med.unc.edu

Dr Landers has no financial interests in the subject matter.

Reference

1. M.B. Landers 3rd et al., Retina, 2012; 32(1):172–176.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.